JP2008517953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517953A5 JP2008517953A5 JP2007538227A JP2007538227A JP2008517953A5 JP 2008517953 A5 JP2008517953 A5 JP 2008517953A5 JP 2007538227 A JP2007538227 A JP 2007538227A JP 2007538227 A JP2007538227 A JP 2007538227A JP 2008517953 A5 JP2008517953 A5 JP 2008517953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antisense
- pharmaceutical composition
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 16
- 239000000074 antisense oligonucleotide Substances 0.000 claims 9
- 238000012230 antisense oligonucleotides Methods 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 206010014950 Eosinophilia Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 102000010790 Interleukin-3 Receptors Human genes 0.000 claims 2
- 108010038452 Interleukin-3 Receptors Proteins 0.000 claims 2
- 102000010786 Interleukin-5 Receptors Human genes 0.000 claims 2
- 108010038484 Interleukin-5 Receptors Proteins 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 1
- 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 claims 1
- 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 claims 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62320604P | 2004-10-29 | 2004-10-29 | |
| US60/623,206 | 2004-10-29 | ||
| PCT/CA2005/001656 WO2006045202A1 (en) | 2004-10-29 | 2005-10-27 | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008517953A JP2008517953A (ja) | 2008-05-29 |
| JP2008517953A5 true JP2008517953A5 (enExample) | 2008-12-11 |
| JP5314283B2 JP5314283B2 (ja) | 2013-10-16 |
Family
ID=36226992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538227A Expired - Fee Related JP5314283B2 (ja) | 2004-10-29 | 2005-10-27 | アレルギーおよび新生物細胞増殖を治療するための、アンチセンスオリゴヌクレオチド |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8119790B2 (enExample) |
| EP (1) | EP1812075B1 (enExample) |
| JP (1) | JP5314283B2 (enExample) |
| CN (1) | CN101087623B (enExample) |
| AU (1) | AU2005299218B2 (enExample) |
| BR (1) | BRPI0517387A8 (enExample) |
| CA (1) | CA2584457C (enExample) |
| ES (1) | ES2450929T3 (enExample) |
| MX (1) | MX2007005083A (enExample) |
| NZ (1) | NZ554723A (enExample) |
| RU (1) | RU2416412C2 (enExample) |
| WO (1) | WO2006045202A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011519579A (ja) | 2008-05-15 | 2011-07-14 | トピジェン ファーマスーティカルズ インク | 炎症および新生細胞増殖の治療のためのオリゴヌクレオチド |
| JP5896175B2 (ja) | 2010-04-29 | 2016-03-30 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | トランスサイレチン発現の調節 |
| SG192869A1 (en) * | 2011-02-24 | 2013-09-30 | Pharmaxis Ltd | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
| US9901079B2 (en) | 2011-08-18 | 2018-02-27 | New York University | Inhibition of oncogenic kras-induced GM-CSF production and function |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| HK1255922A1 (zh) | 2015-11-04 | 2019-09-06 | Astrazeneca Ab | 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3337530A (en) * | 1965-09-20 | 1967-08-22 | Upjohn Co | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US4921757A (en) * | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) * | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4917951A (en) * | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
| GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US6806061B1 (en) * | 1995-01-19 | 2004-10-19 | Children's Medical Center Corporation | G protein-coupled receptor gene and methods of use therefor |
| US5874211A (en) | 1995-04-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Chemokine expressed in eosinophils |
| FR2734147B1 (fr) | 1995-05-19 | 1997-10-10 | Klein Jean Michel | Dispositif d'osteosynthese implantable |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
| US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
| US6229006B1 (en) | 1995-12-22 | 2001-05-08 | Smithkline Beecham Corporation | Use of antisense oligodeoxynucleotides to produce truncated proteins |
| AUPN780096A0 (en) | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| AU2813297A (en) | 1996-04-26 | 1997-11-19 | Incyte Pharmaceuticals, Inc. | Mammalian mixed lymphocyte receptors, chemokine receptors {mmlr-ccr} |
| JP3689118B2 (ja) | 1996-04-26 | 2005-08-31 | メルク エンド カンパニー インコーポレーテッド | 好酸球エオタキシンレセプター |
| US5807708A (en) * | 1996-07-30 | 1998-09-15 | Millennium Pharmaceuticals, Inc. | Conservin nucleic acid molecules and compositions |
| KR20010030622A (ko) | 1997-09-17 | 2001-04-16 | 리차드 알. 이킨 | 다중 표적 하이브리드형성 핵산과 그들의 제조, 구성,제제, 키트 및 응용 |
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| AU4595399A (en) | 1998-06-19 | 2000-01-10 | Mcgill University | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues |
| WO2000009525A2 (en) | 1998-08-03 | 2000-02-24 | East Carolina University | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
| US6175004B1 (en) * | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
| CN1330513A (zh) | 1999-04-06 | 2002-01-09 | 东卡罗来纳大学 | 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法 |
| JP2004507272A (ja) | 2000-09-06 | 2004-03-11 | マクギル ユニバーシティー | アラビノフラノース類似体およびデオキシリボースヌクレオチドのキメラアンチセンス |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| PT1406667E (pt) * | 2001-07-06 | 2008-05-23 | Topigen Pharmaceuticals Inc | Métodos para aumentar a eficácia in vivo de oligonucleótidos e a inibição da inflamação em mamíferos |
| WO2003037909A1 (en) | 2001-10-29 | 2003-05-08 | Mcgill University | Acyclic linker-containing oligonucleotides and uses thereof |
| CA2474414C (en) | 2002-02-01 | 2018-03-06 | Mcgill University | Oligonucleotides comprising alternating segments and uses thereof |
-
2005
- 2005-10-27 US US11/666,647 patent/US8119790B2/en not_active Expired - Fee Related
- 2005-10-27 WO PCT/CA2005/001656 patent/WO2006045202A1/en not_active Ceased
- 2005-10-27 RU RU2007119777/15A patent/RU2416412C2/ru not_active IP Right Cessation
- 2005-10-27 CN CN2005800448619A patent/CN101087623B/zh not_active Expired - Fee Related
- 2005-10-27 AU AU2005299218A patent/AU2005299218B2/en not_active Ceased
- 2005-10-27 NZ NZ554723A patent/NZ554723A/en not_active IP Right Cessation
- 2005-10-27 MX MX2007005083A patent/MX2007005083A/es active IP Right Grant
- 2005-10-27 EP EP05802169.2A patent/EP1812075B1/en not_active Expired - Lifetime
- 2005-10-27 ES ES05802169.2T patent/ES2450929T3/es not_active Expired - Lifetime
- 2005-10-27 BR BRPI0517387A patent/BRPI0517387A8/pt not_active Application Discontinuation
- 2005-10-27 CA CA2584457A patent/CA2584457C/en not_active Expired - Fee Related
- 2005-10-27 JP JP2007538227A patent/JP5314283B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-21 US US13/301,183 patent/US8202851B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534684A5 (enExample) | ||
| Gu et al. | The emerging roles of interstitial macrophages in pulmonary fibrosis: a perspective from scRNA-seq analyses | |
| JP2009539367A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2011512326A5 (enExample) | ||
| JP2015532097A5 (enExample) | ||
| JP2021506238A5 (enExample) | ||
| JP2006500958A5 (enExample) | ||
| JP2017070307A5 (enExample) | ||
| WO2004048594A3 (en) | Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences | |
| JP2008538183A5 (enExample) | ||
| JP2012136542A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| JP2014501492A5 (enExample) | ||
| Van Der Valk et al. | Genomic looping: a key principle of chromatin organization | |
| JP2010088434A5 (enExample) | ||
| WO2007014619A8 (en) | Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | |
| JP2002518007A5 (enExample) | ||
| Savage et al. | RNA-seq identifies a role for the PPARβ/δ inverse agonist GSK0660 in the regulation of TNFα-induced cytokine signaling in retinal endothelial cells | |
| JP2011524745A5 (enExample) | ||
| JP2008517953A5 (enExample) | ||
| JP2009506122A5 (enExample) | ||
| JP2013537404A5 (enExample) |